Gilead's Trodelvy and Keytruda Combination Reduces Death Risk by 35% in TNBC
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Source: Yahoo Finance
- Clinical Trial Success: The ASCENT-04 study demonstrated that the combination of Trodelvy and Keytruda reduced the risk of disease progression or death by 35% (HR: 0.65; p<0.001) in patients with PD-L1+ metastatic triple-negative breast cancer, providing a new treatment option for patients.
- Extended Survival: The median progression-free survival for Trodelvy plus Keytruda was 11.2 months, significantly longer than the 7.8 months observed with chemotherapy plus Keytruda, indicating the combination's critical role in improving patient outcomes.
- Good Safety Profile: The safety profile of Trodelvy plus Keytruda in the ASCENT-04 study was consistent with known safety characteristics, with no new safety signals identified, and a significantly lower discontinuation rate due to adverse events compared to the chemotherapy group (12% vs. 31%), indicating better tolerability.
- Significant Market Potential: With Trodelvy already used in over 50 countries, Gilead aims to establish it as a standard first-line treatment for triple-negative breast cancer through further clinical trials and regulatory submissions, addressing the urgent market need for new therapies.
Analyst Views on GILD
Wall Street analysts forecast GILD stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for GILD is 137.88 USD with a low forecast of 105.00 USD and a high forecast of 154.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
16 Buy
3 Hold
0 Sell
Strong Buy
Current: 140.970
Low
105.00
Averages
137.88
High
154.00
Current: 140.970
Low
105.00
Averages
137.88
High
154.00
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer, and inflammation. It is focused on discovering, developing, and delivering medicines to address unmet medical needs in virology, oncology, and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It has a cancer program, namely TREX1. It operates in more than 35 countries worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
